OFIX CEO Calafiore buys 10,000 shares at $12.54; stock -37.9% from 52-week high, company unprofitable with -$53.1M net income.
Calafiore Massimo, President & CEO, purchased 10,000 shares at $12.54 on 2025-05-09, increasing his holdings to 234.6K shares. The transaction occurs as Orthofix stock has declined 37.9% from its 52-week high of $20.02 and fallen 9.1% over the past 30 days. The company remains unprofitable with negative net income of -$53.1M against revenue of $193.6M, creating an environment where insider buying could reflect opportunistic accumulation at depressed levels or lack of material forward confidence. The company faces significant profitability challenges despite modest 7.1% annual revenue growth. A cluster of 2 other insiders buying within the same 14-day window suggests coordinated interest, though Calafiore's prior cross-ticker buy activity showed an average 30-day return of -16.4%, and his one prior OFIX trade (2025-03-05) also posted a -16.4% 30-day return—a pattern that suggests timing has not favored his recent accumulation.
CEO Calafiore purchases 9,914 shares of OFIX at $17.43; holdings now 222.4K shares amid -16.1% decline from 52-week high and $-27.4M annual loss.
Massimo Calafiore, President & CEO of Orthofix Medical Inc., purchased 9,914 shares at $17.43 on 2025-03-05, increasing his holdings to 222.4K shares. The company is trading at $16.80, a -16.1% decline from the 52-week high of $20.02, and has reported a negative net income of $-27.4M over its most recent full fiscal year despite 7.1% annual revenue growth. This open-market purchase by the chief executive occurs in the context of depressed equity valuation and operational losses, providing a data point on insider positioning but without sufficient context regarding the company's turnaround trajectory or the executive's stated rationale to characterize conviction definitively.
